Genpharm Gains Exclusive Rights to Commercialize Vyvgart ™ (efgartigimod alfa-fcab) in Generalized Myasthenia Gravis in the Middle East

Dubai, United Arab Emirates – January 20th, 2022

Genpharm announced today that it has signed an exclusive partnership with argenx SE under which Genpharm will commercialize VYVGART in the Gulf Region. Vyvgart has been approved by the FDA for treatment of adult patients with generalized Myasthenia Gravis (gMG) who are anti-AChR antibody positive.“This new collaboration consolidates the leadership of Genpharm and solidifies its mission in bringing innovative treatments to rare disease patients across the Middle East. We thank the management team at argenx for their trust. Myasthenia gravis patients and treating physicians can now have a new targeted therapeutic option at their disposal,” says Karim Smaira, Genpharm CEO.

About Myasthenia Gravis

Generalized myasthenia gravis (gMG) is a rare and chronic autoimmune disease where IgG autoantibodies disrupt communication between nerves and muscles, causing debilitating and potentially life-threatening muscle weakness. Approximately 85% of people with MG progress to gMG within 24 months1 , where muscles throughout the body may be affected. Patients with confirmed AChR antibodies account for approximately 85% of the total gMG population.

About argenx

argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx developed and is commercializing the first-and-only FDA approved neonatal Fc receptor blocker, VYVGART™ (efgartigimod alfa-fcab) for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive. The Company is evaluating efgartigimod in multiple serious autoimmune diseases and advancing several earlier stage experimental medicines within its therapeutic franchises. To learn some more go to www.argenx.com